



Technology Brief: Small Molecule Inhibitors of Nuclear Export of Topoisomerase II Alpha for Multiple Myeloma Treatment

Docket Number: 08MB014

<p>Summary</p>	<ul style="list-style-type: none"> • Inhibitors of topoisomerase II, such as doxorubicin, are effective chemotherapy for multiple myeloma. • Resistance to these agents may arise when cancer cells export topoisomerase II alpha from the nucleus to the cytoplasm. • Scientists at Moffitt Cancer Center have identified small molecules that inhibit nuclear export of topoisomerase II alpha and sensitize human myeloma cells to topoisomerase II inhibitors such as doxorubicin. • These newly identified export inhibitors may be useful as agents for treating multiple myeloma and other hematologic cancers, either alone or in combination with topoisomerase II inhibitors.
<p>Features and Benefits</p>	<ul style="list-style-type: none"> • The two nuclear export signals in topoisomerase II alpha were targeted by in silico screening against a library of drug-like molecules. • The 20 top-scoring compounds were assayed for inducing cell death in human multiple myeloma cell lines NCI-H929 and RPMI 8226, both as single agents and in combination with topoisomerase II inhibitors. • Two inhibitors have IC₅₀ values in the low micromolar range as single agents. • Nuclear export inhibitors are synergistic in combination with inhibitors of topoisomerase II in inducing death of human multiple myeloma cells. • These newly identified inhibitors may be useful as single agents in treatment of multiple myeloma, or in combinations to overcome resistance to topoisomerase II inhibitors.
<p>Stage of Development</p>	<p>Proof of concept in human multiple myeloma cell lines. Testing planned in patient cell samples.</p>
<p>Inventors</p>	<p>Daniel Sullivan, MD; Joel Turner, PhD; Thomas Rowe, PhD; David Ostrov, PhD</p>
<p>Patent Status</p>	<p>PCT patent application filed.</p>
<p>Contact Information:</p> <p style="text-align: center;"> Haskell Adler PhD MBA Senior Licensing Manager Email: haskell.adler@moffitt.org Telephone: 813-745-6596 </p> <p style="text-align: center;"> H. Lee Moffitt Cancer Center and Research Institute, Inc. Office of Technology Management and Commercialization 12902 Magnolia Drive MRC-TTO Tampa, FL 33612 Website: http://www.moffitt.org/OTMC </p>	